CCL3-4 in melanoma correlated with increased CD3+, CD8+ T cell infiltration (6, 24), and improved survival (24). Increased CCL4 in melanoma pre- and post- anti-CTLA4 (ipilimumab) treatment was associated with T cell infiltration and response to treatment (27). Here, CD8A is linked to melanoma.